Online inquiry

IVTScrip™ mRNA-Anti-APP, MABT5102A(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10908MR)

This product GTTS-WQ10908MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets APP gene. The antibody can be applied in Alzheimer's disease (AD) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-APP, MABT5102A(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ10908MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ16012MR IVTScrip™ mRNA-Anti-ERBB2, ZW-25(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ZW-25
GTTS-WQ15605MR IVTScrip™ mRNA-Anti-SLC29A2, VAL-1221(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA VAL-1221
GTTS-WQ2681MR IVTScrip™ mRNA-Anti-SOST, AMG 785 (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 785
GTTS-WQ3025MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7&ITGAE, Anti-Beta7(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Anti-Beta7
GTTS-WQ10399MR IVTScrip™ mRNA-Anti-TNFSF13B, LY2127399(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA LY2127399
GTTS-WQ7835MR IVTScrip™ mRNA-Anti-RTN4, GSK-1223249(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GSK-1223249
GTTS-WQ13187MR IVTScrip™ mRNA-Anti-PCSK9, PF-04950615(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PF-04950615
GTTS-WQ12645MR IVTScrip™ mRNA-Anti-RSPO3, OMP-131R10(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA OMP-131R10
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW